DNMT3A and T-cell non-Hodgkin lymphoma: Mutations in DNMT3A have been reported in various hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and T-cell lymphoma and leukemia [30–34], underlining a potent tumor suppressor role.